Using inflammation indices to predict endometrial cancer risk
Inflammatory Index as a Predictor for Endometrial Cancer: an Observational Study
This study is trying to see if certain blood markers related to inflammation can help predict the risk of endometrial cancer in women who are about to have surgery for the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 128 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University of Campania Luigi Vanvitelli Academic / other |
| Locations | 1 site (Naples) |
| Trial ID | NCT05657483 on ClinicalTrials.gov |
What this trial studies
This observational trial aims to identify the association between systemic inflammation indices, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR), and the risk classification of endometrial cancer patients according to European guidelines. Women diagnosed with endometrial cancer who are admitted for surgical treatment will participate in the study, providing venous blood samples for analysis. The goal is to enhance risk stratification by correlating these inflammation indices with various oncological factors, including lymphovascular space invasion and myometrial infiltration.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older who have been histologically diagnosed with endometrial cancer and are undergoing surgical staging.
Not a fit: Patients with chronic inflammatory diseases, synchronous tumors, or those who have received steroid therapy recently may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve risk assessment and treatment planning for patients with endometrial cancer.
How similar studies have performed: Other studies have shown promising results using inflammation indices in cancer prognosis, suggesting this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients histologically diagnosed with endometrial cancer. * Patients undergoing surgical staging of the disease. * Patients undergoing full-body CT-scan 30 days before enrollment. * At least 18-year-old patients. Exclusion Criteria: * Unfit to plead. * Patients with chronic inflammatory diseases (IBDs; rheumatic conditions). * Synchronous tumors or cancer diagnosis in the previous 3 years. * Patients undergoing steroid therapy in the last 30 days prior to recruitment
Where this trial is running
Naples
- Università degli Studi della Campania Luigi Vanvitelli — Naples, Italy (Recruiting)
Study contacts
- Principal investigator: Carlo Ronsini, MD — University of Campania Luigi Vanvitelli
- Study coordinator: Carlo Ronsini, MD
- Email: carlo.ronsini90@gmail.com
- Phone: +393277334102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.